HRP20181462T1 - Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva - Google Patents

Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva

Info

Publication number
HRP20181462T1
HRP20181462T1 HRP20181462TT HRP20181462T HRP20181462T1 HR P20181462 T1 HRP20181462 T1 HR P20181462T1 HR P20181462T T HRP20181462T T HR P20181462TT HR P20181462 T HRP20181462 T HR P20181462T HR P20181462 T1 HRP20181462 T1 HR P20181462T1
Authority
HR
Croatia
Prior art keywords
regorafenib
combination
colorectal cancer
acetylsalicylic acid
treating colorectal
Prior art date
Application number
HRP20181462TT
Other languages
English (en)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181462(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Ag filed Critical Bayer Pharma Aktiengesellschaft
Publication of HRP20181462T1 publication Critical patent/HRP20181462T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20181462TT 2012-09-25 2018-09-12 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva HRP20181462T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
EP13770659.4A EP2900269B1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Publications (1)

Publication Number Publication Date
HRP20181462T1 true HRP20181462T1 (hr) 2018-11-02

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181462TT HRP20181462T1 (hr) 2012-09-25 2018-09-12 Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva

Country Status (29)

Country Link
US (1) US10898500B2 (hr)
EP (1) EP2900269B1 (hr)
JP (1) JP6294888B2 (hr)
KR (1) KR102210575B1 (hr)
CN (1) CN104994876A (hr)
AU (1) AU2013322854B2 (hr)
BR (1) BR112015006686B1 (hr)
CA (1) CA2885688C (hr)
CL (1) CL2015000744A1 (hr)
CY (1) CY1120939T1 (hr)
DK (1) DK2900269T3 (hr)
EA (1) EA032023B1 (hr)
ES (1) ES2687985T3 (hr)
HK (1) HK1214169A1 (hr)
HR (1) HRP20181462T1 (hr)
HU (1) HUE039878T2 (hr)
IL (1) IL237690B (hr)
LT (1) LT2900269T (hr)
MX (1) MX357035B (hr)
MY (1) MY183969A (hr)
NZ (1) NZ705860A (hr)
PH (1) PH12015500587A1 (hr)
PL (1) PL2900269T3 (hr)
PT (1) PT2900269T (hr)
RS (1) RS57875B1 (hr)
SG (2) SG11201501963RA (hr)
SI (1) SI2900269T1 (hr)
WO (1) WO2014048881A1 (hr)
ZA (1) ZA201502840B (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
HUE036117T2 (hu) 2013-11-26 2018-06-28 Hoffmann La Roche Oktahidro-ciklobuta[1,2-C;3,4-C']dipirrol származékok, mint autotaxin inhibitorok
CN106029667B (zh) 2014-03-26 2019-08-23 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1,4]二氮杂*化合物
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
UA123362C2 (uk) 2015-09-04 2021-03-24 Ф. Хоффманн-Ля Рош Аг Феноксиметильні похідні
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CA2991615A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
CN107614505B (zh) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CN117982446A (zh) * 2016-06-28 2024-05-07 阿萨德股份有限公司 双组分组合物
AU2018233079B9 (en) 2017-03-16 2021-07-22 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual ATX/CA inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
PT3630112T (pt) 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002014A1 (fr) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Compositions medicamenteuses destinees au traitement du cancer colorectal
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US8637553B2 (en) * 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CA2628881A1 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
SG11201501963RA (en) 2015-04-29
CY1120939T1 (el) 2019-12-11
EA032023B1 (ru) 2019-03-29
JP6294888B2 (ja) 2018-03-14
DK2900269T3 (en) 2018-10-01
JP2015529234A (ja) 2015-10-05
KR20150060869A (ko) 2015-06-03
RS57875B1 (sr) 2018-12-31
US10898500B2 (en) 2021-01-26
US20150202214A1 (en) 2015-07-23
CL2015000744A1 (es) 2016-01-08
PT2900269T (pt) 2018-10-22
NZ705860A (en) 2018-07-27
BR112015006686B1 (pt) 2022-04-05
EP2900269B1 (en) 2018-08-01
PL2900269T3 (pl) 2019-02-28
KR102210575B1 (ko) 2021-02-02
LT2900269T (lt) 2018-11-12
AU2013322854B2 (en) 2018-07-19
MX357035B (es) 2018-06-25
AU2013322854A1 (en) 2015-04-02
PH12015500587A1 (en) 2015-05-11
CA2885688C (en) 2021-03-02
CA2885688A1 (en) 2014-04-03
MX2015003728A (es) 2015-09-23
HK1214169A1 (zh) 2016-07-22
MY183969A (en) 2021-03-17
SG10201702356VA (en) 2017-04-27
WO2014048881A1 (en) 2014-04-03
HUE039878T2 (hu) 2019-02-28
SI2900269T1 (sl) 2018-10-30
EA201500365A1 (ru) 2015-08-31
ZA201502840B (en) 2017-11-29
CN104994876A (zh) 2015-10-21
IL237690A0 (en) 2015-05-31
EP2900269A1 (en) 2015-08-05
IL237690B (en) 2019-07-31
BR112015006686A2 (pt) 2019-08-27
ES2687985T3 (es) 2018-10-30

Similar Documents

Publication Publication Date Title
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
IL288181A (en) Cancer treatment methods
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1209798A1 (en) Compositions and methods for treating cancer
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
EP2836482A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2890720A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1216854A1 (zh) 用於治療癌症的組合物和方法
EP2928456A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2822593A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF